PrimeGenX Therapeutics Co., Ltd. Files Second Listing Application with HKEX; CITIC Securities and Minsheng Capital Act as Joint Sponsors

NewTimeSpace · 2026/07/27 09:41 · By Mingzhe Sun

NewTimeSpace News: PrimeGenX Therapeutics Co., Ltd. submitted its second listing application to HKEX on 24 July, with CITIC Securities and Minsheng Capital serving as joint sponsors. Founded in 2016, it is a biotech firm focused on local delivery targeted therapies for immune inflammatory diseases. Its core asset PG-011 (Pumecitinib), a small-molecule JAK1/2 inhibitor, is being developed in two formulations: pumecitinib gel for mild-to-moderate atopic dermatitis and pumecitinib nasal spray for moderate-to-severe allergic rhinitis. The Company has 63 R&D personnel, accounting for 73.2% of all full-time employees.

NewTimeSpace News: On 24 July 2026, PrimeGenX Therapeutics Co., Ltd. filed its second listing application with the Hong Kong Stock Exchange, with CITIC Securities and Minsheng Capital appointed as joint sponsors.

Founded in 2016, the Company is a biotechnology enterprise concentrating on local delivery targeted therapies for immune inflammatory diseases. It focuses on therapeutics for chronic inflammatory illnesses, aiming to deliver comprehensive treatment solutions balancing efficacy, safety and long-term patient satisfaction.

Its pipeline comprises self-developed small-molecule candidates. The core product PG-011 (Pumecitinib) is a small-molecule JAK1/2 inhibitor under development in two dosage forms: pumecitinib gel primarily indicated for mild-to-moderate atopic dermatitis, and pumecitinib nasal spray targeting moderate-to-severe allergic rhinitis. Additional pipeline candidates include PG-033 tablets for pruritus, PG-018 tablets for autoimmune nephropathy, PG-040 eye drops for glaucoma, together with five generic drug candidates for various chronic inflammatory disorders.

As of the latest practicable date, the Company employs 63 R&D staff, representing 73.2% of total full-time employees. Core R&D team members possess over 15 years of pharmaceutical industry experience, covering chemistry, biology, pharmacology and clinical medicine.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

PrimeGenX IPO file a listing application